In the anti-hemorrhagic biopharmaceutical market, Korean biosimilar Clotinab is dominating the market. According to data on drug distribution performance, ISU ABXIS Clotinab's 2021 performance was 2.8 billion won, dominating the Abciximab biosimilar market. The sales of the product in 2018, 2019, and 2020 are 3,048 million won, 2,920 million won, and 2.94 billion won, and the cumulative performance of 3Q in 2022 is about 1,88 billion won.

Clotinab's dominance is attributed to the withdrawal of the original biopharmaceutical Lilly Reopro from the market. Clotinab, the first antibody biosimilar title in Korea, challenged Reopro, which boasts 400 billion won in global sales in 2007. In the early days of it